
Avidity’s $300M offering; Rapport raises $174M
Plus, news about Replimmune, Novo Nordisk and Biosplice:
Avidity Biosciences is looking for $300M in stock sale: The RNA company is planning a $300 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.